Healthcare
Halozyme Therapeutics (HALO)
Halozyme Therapeutics stock analysis and opportunity scoring
$107.72
↑ +1.16%
Halozyme Therapeutics (HALO) at a glance
Halozyme Therapeutics (HALO) is a publicly traded company in the Healthcare - Biotechnology sector tracked by MKD Intelligence.
HALO last traded at $82.54 as of 2026-09-03.
MKD Intelligence assigns HALO a composite opportunity score of 55 out of 100, indicating mixed conditions across trend, momentum and volume factors.
The risk score for HALO is 67 out of 100 (high), where a higher number means greater expected volatility.
Price History
High
$109.32
Low
$82.27
Period
Sep 1 - Jul 31 (23d)
Hover for details • Scroll to zoom • Drag to pan • Double-click to reset
Recent News
No recent news available.
Upcoming Events
Data as of Sep 3
This platform provides market intelligence and educational information only. It does not constitute financial advice, and no information presented should be interpreted as a recommendation to buy, sell, or hold any security. Past performance and historical patterns do not guarantee future results.